Laser  ||| S:0 E:6 ||| NNP
and  ||| S:6 E:10 ||| CC
intense  ||| S:10 E:18 ||| JJ
pulsed  ||| S:18 E:25 ||| JJ
light  ||| S:25 E:31 ||| JJ
management  ||| S:31 E:42 ||| NN
of  ||| S:42 E:45 ||| IN
couperose  ||| S:45 E:55 ||| NN
and  ||| S:55 E:59 ||| CC
rosacea  ||| S:59 E:67 ||| JJ
Management  ||| S:67 E:78 ||| NN
of  ||| S:78 E:81 ||| IN
couperosis  ||| S:81 E:92 ||| NN
and  ||| S:92 E:96 ||| CC
rosacea  ||| S:96 E:104 ||| NN
has  ||| S:104 E:108 ||| VBZ
been  ||| S:108 E:113 ||| VBN
totally  ||| S:113 E:121 ||| RB
renewed  ||| S:121 E:129 ||| VBN
by  ||| S:129 E:132 ||| IN
laser  ||| S:132 E:138 ||| NN
and  ||| S:138 E:142 ||| CC
vascular  ||| S:142 E:151 ||| JJ
laser  ||| S:151 E:157 ||| NN
techniques ||| S:157 E:167 ||| NNS
,  ||| S:167 E:169 ||| ,
with  ||| S:169 E:174 ||| IN
efficacy  ||| S:174 E:183 ||| VBG
targeted  ||| S:183 E:192 ||| VBN
on  ||| S:192 E:195 ||| IN
the  ||| S:195 E:199 ||| DT
telangiectases  ||| S:199 E:214 ||| NN
and  ||| S:214 E:218 ||| CC
to  ||| S:218 E:221 ||| TO
a  ||| S:221 E:223 ||| DT
lesser  ||| S:223 E:230 ||| JJR
extent  ||| S:230 E:237 ||| NN
on  ||| S:237 E:240 ||| IN
the  ||| S:240 E:244 ||| DT
erythrosis ||| S:244 E:254 ||| NN
.  ||| S:254 E:256 ||| .
Laser  ||| S:256 E:262 ||| NN
management  ||| S:262 E:273 ||| NN
of  ||| S:273 E:276 ||| IN
hypertrophic  ||| S:276 E:289 ||| JJ
rosacea  ||| S:289 E:297 ||| NN
or  ||| S:297 E:300 ||| CC
rhinophyma  ||| S:300 E:311 ||| NN
depends  ||| S:311 E:319 ||| VBZ
on  ||| S:319 E:322 ||| IN
surgical  ||| S:322 E:331 ||| JJ
treatment  ||| S:331 E:341 ||| NN
with  ||| S:341 E:346 ||| IN
decortication ||| S:346 E:359 ||| NN
,  ||| S:359 E:361 ||| ,
continuous  ||| S:361 E:372 ||| JJ
CO ||| S:372 E:374 ||| NNP
( ||| S:374 E:375 ||| -LRB-
2 ||| S:375 E:376 ||| LS
)  ||| S:376 E:378 ||| -RRB-
ablative  ||| S:378 E:387 ||| JJ
laser  ||| S:387 E:393 ||| NN
or  ||| S:393 E:396 ||| CC
Erbium ||| S:396 E:402 ||| NNP
,  ||| S:402 E:404 ||| ,
fractionated  ||| S:404 E:417 ||| VBG
at  ||| S:417 E:420 ||| IN
high  ||| S:420 E:425 ||| JJ
power ||| S:425 E:430 ||| NN
,  ||| S:430 E:432 ||| ,
then  ||| S:432 E:437 ||| RB
vascular  ||| S:437 E:446 ||| JJ
laser  ||| S:446 E:452 ||| NN
treatment  ||| S:452 E:462 ||| NN
for  ||| S:462 E:466 ||| IN
the  ||| S:466 E:470 ||| DT
telangiectases ||| S:470 E:484 ||| NN
:  ||| S:484 E:486 ||| :
lasers  ||| S:486 E:493 ||| NNS
with  ||| S:493 E:498 ||| IN
pulsed  ||| S:498 E:505 ||| JJ
dye ||| S:505 E:508 ||| NN
,  ||| S:508 E:510 ||| ,
KTP ||| S:510 E:513 ||| NNP
,  ||| S:513 E:515 ||| ,
or  ||| S:515 E:518 ||| CC
pulsed  ||| S:518 E:525 ||| JJ
lights  ||| S:525 E:532 ||| NNS
for  ||| S:532 E:536 ||| IN
red  ||| S:536 E:540 ||| JJ
laser  ||| S:540 E:546 ||| NN
telangiectases  ||| S:546 E:561 ||| NNS
and  ||| S:561 E:565 ||| CC
long  ||| S:565 E:570 ||| RB
pulse  ||| S:570 E:576 ||| JJ
Nd-Yag  ||| S:576 E:583 ||| JJ
laser  ||| S:583 E:589 ||| NN
for  ||| S:589 E:593 ||| IN
blue  ||| S:593 E:598 ||| JJ
telangiectases ||| S:598 E:612 ||| NN
.  ||| S:612 E:614 ||| .
For  ||| S:614 E:618 ||| IN
papulopustular  ||| S:618 E:633 ||| JJ
rosacea ||| S:633 E:640 ||| NN
,  ||| S:640 E:642 ||| ,
vascular  ||| S:642 E:651 ||| JJ
laser  ||| S:651 E:657 ||| NN
treatment  ||| S:657 E:667 ||| NN
( ||| S:667 E:668 ||| -LRB-
pulsed  ||| S:668 E:675 ||| JJ
dye  ||| S:675 E:679 ||| NN
and  ||| S:679 E:683 ||| CC
KTP ||| S:683 E:686 ||| NNP
)  ||| S:686 E:688 ||| -RRB-
and  ||| S:688 E:692 ||| CC
intense  ||| S:692 E:700 ||| JJ
pulsed  ||| S:700 E:707 ||| JJ
light  ||| S:707 E:713 ||| NN
will  ||| S:713 E:718 ||| MD
be  ||| S:718 E:721 ||| VB
begun  ||| S:721 E:727 ||| VBN
once  ||| S:727 E:732 ||| IN
the  ||| S:732 E:736 ||| DT
inflammation  ||| S:736 E:749 ||| NN
has  ||| S:749 E:753 ||| VBZ
been  ||| S:753 E:758 ||| VBN
treated ||| S:758 E:765 ||| VBN
.  ||| S:765 E:767 ||| .
The  ||| S:767 E:771 ||| DT
major  ||| S:771 E:777 ||| JJ
indication  ||| S:777 E:788 ||| NN
for  ||| S:788 E:792 ||| IN
vascular  ||| S:792 E:801 ||| JJ
lasers  ||| S:801 E:808 ||| NNS
and  ||| S:808 E:812 ||| CC
intense  ||| S:812 E:820 ||| JJ
pulsed  ||| S:820 E:827 ||| JJ
light  ||| S:827 E:833 ||| NN
is  ||| S:833 E:836 ||| VBZ
found  ||| S:836 E:842 ||| VBN
in  ||| S:842 E:845 ||| IN
erythematotelangiectatic  ||| S:845 E:870 ||| JJ
rosacea ||| S:870 E:877 ||| NN
,  ||| S:877 E:879 ||| ,
with  ||| S:879 E:884 ||| IN
high  ||| S:884 E:889 ||| JJ
efficacy  ||| S:889 E:898 ||| NN
for  ||| S:898 E:902 ||| IN
the  ||| S:902 E:906 ||| DT
telangiectases ||| S:906 E:920 ||| NN
.  ||| S:920 E:922 ||| .
Diffuse  ||| S:922 E:930 ||| JJ
erythrosis  ||| S:930 E:941 ||| NN
is  ||| S:941 E:944 ||| VBZ
difficult  ||| S:944 E:954 ||| JJ
to  ||| S:954 E:957 ||| TO
treat ||| S:957 E:962 ||| VB
,  ||| S:962 E:964 ||| ,
requiring  ||| S:964 E:974 ||| VBG
a  ||| S:974 E:976 ||| DT
high  ||| S:976 E:981 ||| JJ
number  ||| S:981 E:988 ||| NN
of  ||| S:988 E:991 ||| IN
laser  ||| S:991 E:997 ||| NN
and ||| S:997 E:1000 ||| CC
/ ||| S:1000 E:1001 ||| NNP
or  ||| S:1001 E:1004 ||| CC
intense  ||| S:1004 E:1012 ||| JJ
pulsed  ||| S:1012 E:1019 ||| JJ
light  ||| S:1019 E:1025 ||| JJ
sessions ||| S:1025 E:1033 ||| NNS
.  ||| S:1033 E:1035 ||| .
